Impact of Imaging Study Frequency on Progression Free Survival in Alliance Clinical Trials Enrolling Patients with Untreated Follicular Lymphoma
      Google Scholar   
Citation:
j Clin Oncol vol 41 (16S) 7520
Meeting Instance:
ASCO 2023
Year:
2023
Type:
Abstract
Sub type:
Poster Discussion
Funding:
NCTN
Endpoint:
Secondary-not-in-original
Analysis:
Meta-Analysis
Data Sharing:
Alliance-data-source,-internal-user
Status:
Presented/Published
Citation Status:
pub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Parents:
None
Children:
4120  
Program:
OGC
Primary Committee:
Lymphoma
Sec. Committees:
   
Pharmas:
Celegene (CALGB 50803), GSK (CALGB 50901 and 50904)  
Grants:
U10 CA180821, U10 CA180882  
Corr. Author:
 
Authors:
                         
Networks:
CAPITAL, LAPS-IL057, LAPS-MN026, LAPS-MO011, LAPS-OH007, NY018   
Study
Alliance-A151737
Multiple Studies, or Legacy Studies in Alliance Study:
Alliance-A051103, CALGB-50701, CALGB-50803, CALGB-50901, CALGB-50904
Phases:
N/A, 1, 2
Keywords: